GLENMARKPharmaceuticals
Glenmark Pharmaceuticals Ltd — Balance Sheet
₹2170.50
+0.82%
Glenmark Pharmaceuticals Ltd Balance Sheet (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Ordinary Shares Number | 28.22 Cr | 28.22 Cr | 28.22 Cr | 28.22 Cr | — |
| Share Issued | 28.22 Cr | 28.22 Cr | 28.22 Cr | 28.22 Cr | — |
| Net Debt | 518.49 Cr | — | 3.19K Cr | 2.26K Cr | 3.55K Cr |
| Total Debt | 2.47K Cr | 1.23K Cr | 4.61K Cr | 3.96K Cr | — |
| Tangible Book Value | 7.39K Cr | 6.51K Cr | 7.06K Cr | 6.80K Cr | — |
| Invested Capital | 11.04K Cr | 8.84K Cr | 13.82K Cr | 12.76K Cr | — |
| Working Capital | 3.33K Cr | 1.61K Cr | 5.62K Cr | 3.59K Cr | — |
| Net Tangible Assets | 7.39K Cr | 6.51K Cr | 7.06K Cr | 6.80K Cr | — |
| Capital Lease Obligations | 278.47 Cr | 240.33 Cr | 260.16 Cr | 291.67 Cr | — |
| Common Stock Equity | 8.85K Cr | 7.85K Cr | 9.47K Cr | 9.09K Cr | — |
| Total Capitalization | 9.36K Cr | 7.85K Cr | 13.33K Cr | 11.66K Cr | — |
| Total Equity Gross Minority Interest | 8.85K Cr | 7.85K Cr | 9.84K Cr | 9.44K Cr | — |
| Minority Interest | -0.37 Cr | -0.38 Cr | 365.34 Cr | 351.47 Cr | — |
| Stockholders Equity | 8.85K Cr | 7.85K Cr | 9.47K Cr | 9.09K Cr | — |
| Other Equity Interest | 8.82K Cr | 24.91 Cr | 17.62 Cr | 16.30 Cr | — |
| Capital Stock | 28.22 Cr | 28.22 Cr | 28.22 Cr | 28.22 Cr | — |
| Common Stock | 28.22 Cr | 28.22 Cr | 28.22 Cr | 28.22 Cr | — |
| Total Liabilities Net Minority Interest | 7.20K Cr | 6.51K Cr | 9.53K Cr | 7.65K Cr | — |
| Total Non Current Liabilities Net Minority Interest | 1.23K Cr | 692.49 Cr | 4.43K Cr | 2.96K Cr | — |
| Non Current Deferred Taxes Liabilities | 58.59 Cr | 0.28 Cr | 0.51 Cr | 31.50 Cr | — |
| Long Term Debt And Capital Lease Obligation | 698.91 Cr | 151.69 Cr | 4.03K Cr | 2.77K Cr | — |
| Long Term Capital Lease Obligation | 186.21 Cr | 151.69 Cr | 177.12 Cr | 199.99 Cr | — |
| Long Term Debt | 512.70 Cr | 0.00 | 3.85K Cr | 2.57K Cr | — |
| Current Liabilities | 5.97K Cr | 5.82K Cr | 5.11K Cr | 4.69K Cr | — |
| Other Current Liabilities | 199.00 Cr | 87.72 Cr | 5.87 Cr | 12.22 Cr | — |
| Current Debt And Capital Lease Obligation | 1.77K Cr | 1.08K Cr | 578.62 Cr | 1.19K Cr | — |
| Current Capital Lease Obligation | 92.26 Cr | 88.64 Cr | 83.04 Cr | 91.68 Cr | — |
| Current Debt | 1.68K Cr | 990.60 Cr | 495.58 Cr | 1.10K Cr | — |
| Current Provisions | 596.08 Cr | 641.12 Cr | 492.01 Cr | 491.38 Cr | — |
| Payables | 2.61K Cr | 3.10K Cr | 2.37K Cr | 2.58K Cr | — |
| Total Tax Payable | 28.37 Cr | 290.95 Cr | 98.50 Cr | 93.12 Cr | — |
| Accounts Payable | 2.58K Cr | 2.54K Cr | 2.00K Cr | 2.29K Cr | — |
| Total Assets | 16.05K Cr | 14.36K Cr | 19.37K Cr | 17.08K Cr | — |
| Total Non Current Assets | 6.75K Cr | 6.93K Cr | 8.65K Cr | 8.80K Cr | — |
| Other Non Current Assets | 179.03 Cr | 149.23 Cr | 153.86 Cr | -1.60K Cr | — |
| Non Current Deferred Taxes Assets | 1.12K Cr | 1.05K Cr | 1.81K Cr | 1.69K Cr | — |
| Investmentin Financial Assets | 129.30 Cr | 795.80 Cr | 47.28 Cr | 55.66 Cr | — |
| Available For Sale Securities | 129.30 Cr | 46.14 Cr | 42.70 Cr | 51.04 Cr | — |
| Goodwill And Other Intangible Assets | 1.46K Cr | 1.33K Cr | 2.42K Cr | 2.29K Cr | — |
| Other Intangible Assets | 1.39K Cr | 1.27K Cr | 2.34K Cr | 2.23K Cr | — |
| Goodwill | 70.27 Cr | 67.36 Cr | 73.62 Cr | 60.02 Cr | — |
| Net PPE | 3.86K Cr | 3.57K Cr | 4.22K Cr | 4.65K Cr | — |
| Gross PPE | 3.86K Cr | 6.06K Cr | 6.49K Cr | 6.66K Cr | — |
| Construction In Progress | 541.99 Cr | 449.67 Cr | 1.09K Cr | 962.92 Cr | — |
| Other Properties | 3.32K Cr | 3.12K Cr | 3.90K Cr | 249.07 Cr | — |
| Current Assets | 9.30K Cr | 7.43K Cr | 10.73K Cr | 8.28K Cr | — |
| Other Current Assets | 1.16K Cr | 1.22K Cr | 1.15K Cr | 277.10 Cr | — |
| Inventory | 3.03K Cr | 2.51K Cr | 2.37K Cr | 2.50K Cr | — |
| Taxes Receivable | 0.00 | 670.98 Cr | 485.14 Cr | 480.02 Cr | — |
| Accounts Receivable | 3.34K Cr | 1.86K Cr | 3.67K Cr | 3.10K Cr | — |
| Cash Cash Equivalents And Short Term Investments | 1.77K Cr | 1.67K Cr | 1.17K Cr | 1.44K Cr | — |
| Other Short Term Investments | 91.97 Cr | 12.13 Cr | 14.09 Cr | 32.88 Cr | — |
| Cash And Cash Equivalents | 1.68K Cr | 1.66K Cr | 1.16K Cr | 1.41K Cr | — |
| Retained Earnings | — | 7.87K Cr | 9.46K Cr | 9.21K Cr | 7.23K Cr |
| Additional Paid In Capital | — | 1.71K Cr | 1.71K Cr | 1.71K Cr | 1.71K Cr |
| Other Non Current Liabilities | — | 1.69 Cr | 1.33 Cr | 0.92 Cr | 60.07 Cr |
| Non Current Deferred Revenue | — | 131.94 Cr | 131.85 Cr | 121.32 Cr | 136.61 Cr |
| Other Payable | — | 273.92 Cr | 267.97 Cr | 196.25 Cr | 217.01 Cr |
| Dividends Payable | — | 1.19 Cr | 1.10 Cr | 0.99 Cr | 1.06 Cr |
| Non Current Prepaid Assets | — | 182.63 Cr | 155.18 Cr | 120.20 Cr | 118.94 Cr |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | — | 749.66 Cr | 4.57 Cr | 4.62 Cr | 4.62 Cr |
| Accumulated Depreciation | — | -2.49K Cr | -2.26K Cr | -2.00K Cr | -1.51K Cr |
| Machinery Furniture Equipment | — | 3.28K Cr | 3.26K Cr | 3.46K Cr | 2.84K Cr |
| Buildings And Improvements | — | 2.28K Cr | 2.09K Cr | 2.16K Cr | 1.31K Cr |
| Land And Improvements | — | 46.13 Cr | 42.34 Cr | 68.90 Cr | 58.13 Cr |
| Properties | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Assets Held For Sale Current | — | 0.00 | 2.30K Cr | — | — |
| Restricted Cash | — | 1.19 Cr | 1.10 Cr | 0.99 Cr | 1.06 Cr |
| Prepaid Assets | — | 568.88 Cr | 641.23 Cr | 706.51 Cr | 882.50 Cr |
| Other Inventories | — | 314.09 Cr | 297.67 Cr | 269.29 Cr | 229.74 Cr |
| Finished Goods | — | 1.41K Cr | 1.23K Cr | 1.02K Cr | 972.38 Cr |
| Work In Process | — | 103.11 Cr | 84.15 Cr | 402.48 Cr | 439.45 Cr |
| Raw Materials | — | 690.21 Cr | 762.82 Cr | 807.58 Cr | 635.26 Cr |
| Other Receivables | — | 145.17 Cr | 84.10 Cr | 50.46 Cr | 37.76 Cr |
| Allowance For Doubtful Accounts Receivable | — | -130.84 Cr | -141.19 Cr | -129.86 Cr | -106.75 Cr |
| Gross Accounts Receivable | — | 1.99K Cr | 3.81K Cr | 3.23K Cr | 2.68K Cr |
| Cash Financial | — | 1.66K Cr | 1.16K Cr | 1.41K Cr | 1.14K Cr |
| Pensionand Other Post Retirement Benefit Plans Current | — | — | — | 491.38 Cr | 514.33 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Glenmark Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.